1. Anti-infection Metabolic Enzyme/Protease
  2. HIV HIV Protease SARS-CoV
  3. Lopinavir

Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.

For research use only. We do not sell to patients.

Lopinavir Chemical Structure

Lopinavir Chemical Structure

CAS No. : 192725-17-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
50 mg USD 50 In-stock
100 mg USD 80 In-stock
250 mg USD 160 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Lopinavir:

Top Publications Citing Use of Products

    Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Nov 10;105463.  [Abstract]

    Lopinavir (LPV) (0, 1, 5, 10, 20 μM; 24 h) inhibits autophagy in U87 cells in a dose-dependent manner.

    Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Nov 10;105463.  [Abstract]

    Lopinavir (LPV) (1, 5, 10, 20, 50 µM; 12, 24, 36, 48 h) inhibits the growth of U87 cells.

    View All HIV Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

    IC50 & Target

    HIV-1

     

    Cellular Effect
    Cell Line Type Value Description References
    Caco-2 IC50
    19.11 μM
    Compound: LOPINAVIR
    Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
    Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
    10.21203/rs.3.rs-23951/v1
    Caco-2 CC50
    2128.78 μM
    Compound: LOPINAVIR
    Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
    Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
    10.21203/rs.3.rs-23951/v1
    CCRF-CEM EC50
    260 nM
    Compound: LPV
    Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    [PMID: 17576848]
    CCRF-CEM EC50
    28 nM
    Compound: LPV
    Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    [PMID: 17576848]
    CCRF-CEM EC50
    340 nM
    Compound: LPV
    Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    [PMID: 17576848]
    CCRF-CEM EC50
    35 nM
    Compound: LPV
    Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
    [PMID: 17576848]
    HEK293 EC50
    2.8 nM
    Compound: LPV
    Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay
    Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay
    [PMID: 17638694]
    HEK-293T EC50
    160 nM
    Compound: lopinavir
    Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    [PMID: 22148316]
    HepG2 CC50
    27.8 μM
    Compound: LPV
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay
    10.1039/C1MD00147G
    Huh-7 CC50
    > 37.6 μM
    Compound: 6a
    Cytotoxicity against human Huh-7 cells incubated for 1 hr by MTS assay
    Cytotoxicity against human Huh-7 cells incubated for 1 hr by MTS assay
    [PMID: 32845145]
    MT2 CC50
    > 100 μM
    Compound: LPV
    Cytotoxicity against human MT2 cells after 7 days by MTT assay
    Cytotoxicity against human MT2 cells after 7 days by MTT assay
    [PMID: 20439612]
    MT2 CC50
    > 100 μM
    Compound: lopinavir, LPV
    Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT2 EC50
    0.0026 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT2 EC50
    0.0049 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT2 EC50
    0.007 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT2 EC50
    0.028 μM
    Compound: LPV
    Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay
    [PMID: 20439612]
    MT2 EC50
    0.032 μM
    Compound: LPV
    Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay
    Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay
    [PMID: 18955518]
    MT2 EC50
    0.035 μM
    Compound: LPV
    Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay
    Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay
    [PMID: 20439612]
    MT2 EC50
    0.039 μM
    Compound: LPV
    Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay
    Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay
    [PMID: 20439612]
    MT2 EC50
    4.8 nM
    Compound: LPV
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    [PMID: 19104010]
    MT2 EC50
    5.6 nM
    Compound: LPV
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay
    10.1039/C1MD00147G
    MT2 CC50
    67.9 μM
    Compound: LPV
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay
    10.1039/C1MD00147G
    MT4 EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay
    [PMID: 20439612]
    MT4 EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay
    [PMID: 20439612]
    MT4 EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay
    Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay
    [PMID: 20439612]
    MT4 EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay
    [PMID: 20439612]
    MT4 EC50
    > 10000 nM
    Compound: LPV
    Antiviral activity against HIV1 bearing protease gene with P25 mutation infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 bearing protease gene with P25 mutation infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19323562]
    MT4 EC50
    > 10000 nM
    Compound: LPV
    Antiviral activity against HIV1 P25 infected in human MT4 cells harboring protease L10F, G16E, V32I, M46I, I47A, H69Y, I84V, and T91S mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post in
    Antiviral activity against HIV1 P25 infected in human MT4 cells harboring protease L10F, G16E, V32I, M46I, I47A, H69Y, I84V, and T91S mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post in
    [PMID: 18212102]
    MT4 EC50
    0.01 μM
    Compound: LPV, lopinavir
    Antiviral activity against HIV1 infected MT4 cells by MTT method
    Antiviral activity against HIV1 infected MT4 cells by MTT method
    [PMID: 17696512]
    MT4 EC50
    0.016 μM
    Compound: Lopinavir
    Antiviral activity against HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 19954246]
    MT4 EC50
    0.018 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.019 μM
    Compound: LPV
    Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay
    [PMID: 17638694]
    MT4 EC50
    0.024 μM
    Compound: lopinavir, LPV
    Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.025 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.03 μM
    Compound: Lopinavir
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 19954246]
    MT4 EC50
    0.031 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay
    Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.033 μM
    Compound: lopinavir, LPV
    Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.034 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 IC50
    0.035 μM
    Compound: Lopinavir
    Cytotoxicity against human MT4 cells after 5 days by XTT assay
    Cytotoxicity against human MT4 cells after 5 days by XTT assay
    [PMID: 21741133]
    MT4 EC50
    0.037 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.046 μM
    Compound: LPV
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.06 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.11 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.12 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay
    Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.14 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.14 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E
    Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E
    [PMID: 18955518]
    MT4 EC50
    0.16 μM
    Compound: lopinavir, LPV
    Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.19 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay
    Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.19 μM
    Compound: lopinavir, LPV
    Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.23 μM
    Compound: lopinavir, LPV
    Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.26 μM
    Compound: lopinavir, LPV
    Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.27 μM
    Compound: lopinavir, LPV
    Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.28 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.29 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.3 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    0.31 μM
    Compound: lopinavir, LPV
    Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
    [PMID: 17371811]
    MT4 EC50
    0.33 μM
    Compound: LPV
    Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay
    Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay
    [PMID: 20439612]
    MT4 EC50
    0.385 μM
    Compound: Lopinavir
    Antiviral activity against indinavir-resistant HIV1 harboring L10R/M46I/L63P/V82T/I84V mutant protease infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against indinavir-resistant HIV1 harboring L10R/M46I/L63P/V82T/I84V mutant protease infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 19954246]
    MT4 EC50
    0.7 μM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA
    Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA
    [PMID: 18955518]
    MT4 EC50
    10 nM
    Compound: LPV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay
    [PMID: 19961222]
    MT4 EC50
    1057 nM
    Compound: LPV
    Antiviral activity against HIV1 bearing protease gene with A17 mutation infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 bearing protease gene with A17 mutation infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19323562]
    MT4 EC50
    1057 nM
    Compound: LPV
    Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection meas
    Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection meas
    [PMID: 18212102]
    MT4 EC50
    15 nM
    Compound: LPV
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 17576848]
    MT4 EC50
    15 nM
    Compound: LPV
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 1 passage
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 1 passage
    [PMID: 17576848]
    MT4 EC50
    151 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay
    [PMID: 18212102]
    MT4 EC50
    152 nM
    Compound: LPV
    Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay in presence of 50% human serum
    Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay in presence of 50% human serum
    [PMID: 21899332]
    MT4 EC50
    152 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay in presence of 50% human serum
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay in presence of 50% human serum
    [PMID: 19323562]
    MT4 EC50
    18 nM
    Compound: LPV
    Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay
    Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay
    [PMID: 21899332]
    MT4 EC50
    18 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19323562]
    MT4 EC50
    18 nM
    Compound: LPV
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    [PMID: 17576848]
    MT4 EC50
    18 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
    [PMID: 18212102]
    MT4 CC50
    28 μM
    Compound: LPV
    Cytotoxicity against human MT4 cells after 6 days by MTT assay
    Cytotoxicity against human MT4 cells after 6 days by MTT assay
    [PMID: 17638694]
    MT4 EC50
    30 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay
    Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay
    [PMID: 18212102]
    MT4 EC50
    32 nM
    Compound: LPV
    Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
    Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
    [PMID: 18212102]
    MT4 EC50
    3790 nM
    Compound: LPV
    Antiviral activity against HIV1 bearing protease gene with B26 mutation infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 bearing protease gene with B26 mutation infected in human MT4 cells after 5 days by MTT assay
    [PMID: 19323562]
    MT4 EC50
    3790 nM
    Compound: LPV
    Antiviral activity against HIV1 B26 infected in human MT4 cells harboring protease L33F, K45I, M46I, I50V, I54V, A71V, and V82F mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infectio
    Antiviral activity against HIV1 B26 infected in human MT4 cells harboring protease L33F, K45I, M46I, I50V, I54V, A71V, and V82F mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infectio
    [PMID: 18212102]
    MT4 EC50
    515 nM
    Compound: LPV
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 18 passages
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 18 passages
    [PMID: 17576848]
    MT4 EC50
    6 nM
    Compound: LPV
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
    Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
    [PMID: 17576848]
    PBMC EC50
    > 0.16 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-G infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-G infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 0.3 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-B infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-B infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 0.36 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-TM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-TM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 0.38 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-MM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-MM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 0.4365 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 0.7 μM
    Compound: 6; LPV
    Antiviral activity against multidrug-resistant HIV1-JSL infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against multidrug-resistant HIV1-JSL infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    > 1 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    > 1000 nM
    Compound: 6; LPV
    Antiviral activity against darunavir-resistant HIV1 10P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against darunavir-resistant HIV1 10P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    > 1000 nM
    Compound: 6; LPV
    Antiviral activity against darunavir-resistant HIV1 20P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against darunavir-resistant HIV1 20P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    0.007 μM
    Compound: 6; LPV
    Antiviral activity against wild type HIV1 ERS104pre infected in human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    Antiviral activity against wild type HIV1 ERS104pre infected in human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
    [PMID: 26799988]
    PBMC EC50
    0.034 μM
    Compound: LPV
    Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    0.26 μM
    Compound: LPV
    Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay
    Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay
    [PMID: 20439612]
    PBMC EC50
    15 nM
    Compound: LPV
    Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
    Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
    [PMID: 17576848]
    Vero CC50
    > 50 μM
    Compound: Lopinavir
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
    10.1101/2020.03.20.999730
    Vero IC50
    9.12 μM
    Compound: Lopinavir
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
    10.1101/2020.03.20.999730
    Vero C1008 CC50
    > 32 μM
    Compound: 6a
    Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by the MTS assay
    Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by the MTS assay
    [PMID: 32845145]
    In Vitro

    HIV-1 protease is an essential enzyme for production of mature, infective virus[1].
    Lopinavir potently inhibits wild-type and mutant HIV protease (Ki= 1.3 to 3.6 pM), blocks the replication HIV type 1 (EC50=0.006 to 0.017 μM), and maintains high potency against mutant HIV selected by Ritonavir in vivo (EC50=≤0.06 μM)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Coadministration with low-dose Ritonavir significantly improves the pharmacokinetic properties and hence the activity of Lopinavir against HIV-1 protease[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    628.80

    Formula

    C37H48N4O5

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC1=C(OCC(N[C@@H](CC2=CC=CC=C2)[C@@H](O)C[C@H](CC3=CC=CC=C3)NC([C@H](C(C)C)N4C(NCCC4)=O)=O)=O)C(C)=CC=C1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 250 mg/mL (397.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.5903 mL 7.9517 mL 15.9033 mL
    5 mM 0.3181 mL 1.5903 mL 3.1807 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 25 mg/mL (39.76 mM); Clear solution

      This protocol yields a clear solution of ≥ 25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (250.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  Corn Oil

      Solubility: 20 mg/mL (31.81 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.87%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.5903 mL 7.9517 mL 15.9033 mL 39.7583 mL
    5 mM 0.3181 mL 1.5903 mL 3.1807 mL 7.9517 mL
    10 mM 0.1590 mL 0.7952 mL 1.5903 mL 3.9758 mL
    15 mM 0.1060 mL 0.5301 mL 1.0602 mL 2.6506 mL
    20 mM 0.0795 mL 0.3976 mL 0.7952 mL 1.9879 mL
    25 mM 0.0636 mL 0.3181 mL 0.6361 mL 1.5903 mL
    30 mM 0.0530 mL 0.2651 mL 0.5301 mL 1.3253 mL
    40 mM 0.0398 mL 0.1988 mL 0.3976 mL 0.9940 mL
    50 mM 0.0318 mL 0.1590 mL 0.3181 mL 0.7952 mL
    60 mM 0.0265 mL 0.1325 mL 0.2651 mL 0.6626 mL
    80 mM 0.0199 mL 0.0994 mL 0.1988 mL 0.4970 mL
    100 mM 0.0159 mL 0.0795 mL 0.1590 mL 0.3976 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lopinavir
    Cat. No.:
    HY-14588
    Quantity:
    MCE Japan Authorized Agent: